[1] |
Colombo AL, Padovan AC, Chaves GM. Current knowledge of Trichosporon spp. and Trichosporonosis[J]. Clin Microbiol Rev, 2011,24(4):682⁃700. doi: 10.1128/CMR.00003⁃11.
|
[2] |
廖勇, 杨苏腾, 丛林, 等. 格尔德霉素和环孢素联合常用抗真菌药对阿萨希毛孢子菌临床株体外药敏研究[J]. 实用皮肤病学杂志, 2018,11(2):67⁃70. doi: 10.11786/sypfbxzz.1674⁃1293. 20180202.
|
[3] |
杨蓉娅, 敖俊红, 王文岭, 等. 阿萨希丝孢酵母引起播散性毛孢子菌病国内首例报告[J]. 中华皮肤科杂志, 2001,34(5):329⁃332. doi: 10.3760/j.issn:0412⁃4030.2001.05.001.
|
[4] |
Liao Y, Zhao H, Lu X, et al. Efficacy of ethanol against Trichosporon asahii biofilm in vitro[J]. Med Mycol, 2015,53(4):396⁃404. doi: 10.1093/mmy/myv006.
|
[5] |
de Almeida Júnior JN, Hennequin C. Invasive Trichosporon infection: a systematic review on a re⁃emerging fungal pathogen[J]. Front Microbiol, 2016,7:1629. doi: 10.3389/fmicb.2016. 01629.
|
[6] |
Arendrup MC, Boekhout T, Akova M, et al. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of rare invasive yeast infections[J]. Clin Microbiol Infect, 2014,20 Suppl 3:76⁃98. doi: 10.1111/1469⁃0691.12360.
|
[7] |
Ruan SY, Chien JY, Hsueh PR. Invasive trichosporonosis caused by Trichosporon asahii and other unusual Trichosporon species at a medical center in Taiwan[J]. Clin Infect Dis, 2009,49(1):e11⁃e17. doi: 10.1086/599614.
|
[8] |
Vashishtha VM, Mittal A, Garg A. A fatal outbreak of Trichosporon asahii sepsis in a neonatal intensive care Unit[J]. Indian Pediatr, 2012,49(9):745⁃747. doi: 10.1007/s13312⁃012⁃0137⁃y.
|
[9] |
Basu S, Tilak R, Kumar A. Multidrug⁃resistant Trichosporon: an unusual fungal sepsis in preterm neonates[J]. Pathog Glob Health, 2015,109(4):202⁃206. doi: 10.1179/2047773215Y.000 0000019.
|
[10] |
郎德休, 杨鑫, 廖勇, 等. 阿萨希毛孢子菌胞外分泌酶和药物敏感性的微进化研究[J]. 中华医院感染学杂志, 2019,29(9):1293⁃1296. doi: 10.11816/cn.ni.2019⁃186156.
|
[11] |
Xie Z, Thompson A, Sobue T, et al. Candida albicans biofilms do not trigger reactive oxygen species and evade neutrophil killing[J]. J Infect Dis, 2012,206(12):1936⁃1945. doi: 10.1093/infdis/jis607.
|
[12] |
Marbach H, Mayer K, Vogl C, et al. Within⁃host evolution of bovine Staphylococcus aureus selects for a SigB⁃deficient pathotype characterized by reduced virulence but enhanced proteolytic activity and biofilm formation[J]. Sci Rep, 2019,9(1):13479. doi: 10.1038/s41598⁃019⁃49981⁃6.
|
[13] |
Chandra J, Kuhn DM, Mukherjee PK, et al. Biofilm formation by the fungal pathogen Candida albicans: development, architecture, and drug resistance[J]. J Bacteriol, 2001,183(18):5385⁃5394. doi: 10.1128/jb.183.18.5385⁃5394.2001.
|
[14] |
Baillie GS, Douglas LJ. Effect of growth rate on resistance of Candida albicans biofilms to antifungal agents[J]. Antimicrob Agents Chemother, 1998,42(8):1900⁃1905. doi: 10.1128/AAC. 42.8.1900.
|
[15] |
Taff HT, Mitchell KF, Edward JA, et al. Mechanisms of Candida biofilm drug resistance[J]. Future Microbiol, 2013,8(10):1325⁃1337. doi: 10.2217/fmb.13.101.
|